Reaction
Immune-Mediated Pneumonitis reporting signals
As of the last recalculation, Immune-Mediated Pneumonitis appears in 234 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 196.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 117 | 196.8 | 197.1 |
| Nivolumab | 71 | 93.3 | 93.4 |
| Durvalumab | 19 | 90.3 | 90.4 |
| Ipilimumab | 33 | 79.0 | 79.1 |
| Pemetrexed Disodium | 29 | 77.1 | 77.2 |
| Atezolizumab | 14 | 34.0 | 34.1 |